Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06828796
PHASE2

Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide

Sponsor: Northside Hospital, Inc.

View on ClinicalTrials.gov

Summary

To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2025-07-03

Completion Date

2028-06-30

Last Updated

2025-10-30

Healthy Volunteers

No

Interventions

DRUG

Tacrolimus

Begins Day -1 and continues to Day +90 or Day +180 after transplant

DRUG

Cyclophosphamide

Given Days +3 and +4 after transplant

DRUG

Mycofenolate mofetil

Given Day 0 to Day +35 after transplant

Locations (1)

Northside Hospital

Atlanta, Georgia, United States